The European Medicines Agency (EMA), after initial rejection based on an unfavourable risk-benefit balance, recently recommended approval of lecanemab for treating people with mild cognitive ...

A group of expert neurologists have expressed concerns at the European Commission’s (EC) decision to formally approve the Alzheimer’s drug lecanemab (Leqembi) despite uncertain benefits. Lecanemab, ...